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LIST OF ABBREVIATIONS
 
26 
COPD=Chronic obstructive pulmonary disease; C= Controls; CB= chronic bronchitis; S= smokers; 27 
Mini-BAL=  mini-bronchoalveolar lavage; TLR= Toll like receptor; Foxp3=f forkhead box P3; IP-28 
10= interferon gamma induced protein 10; IL-8= interleukin 8.  29 
30 
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SUMMARY 40 
Background. Chronic bronchitis (CB) is a risk factor in chronic obstructive pulmonary disease 41 
(COPD) for accelerated lung function decline and increased mortality. The lung and systemic 42 
inflammatory and immunological profile of COPD patients with CB which acutely experience 43 
respiratory failure upon a disease exacerbation is unknown.  44 
Methods. In this study, we explored the expression of Foxp3 by western blot analysis, TLR4 by 45 
immunocytochemistry and the concentrations of IP-10 and IL-8 by ELISA in the mini-46 
bronchoalveolar lavages (mini-BAL) and in the peripheral blood of patients with respiratory failure 47 
requiring intubation and mechanical ventilation. The recruited subjects were separated into three 48 
different groups: smokers with CB and COPD (COPD, n=18), smokers with CB but without COPD 49 
(S, n=8) and patients without CB and without COPD (C, n=10). 50 
Results. In mini-BAL of COPD group, Foxp3 and IP-10 were significantly reduced while TLR4 51 
was significantly increased in comparison to C. TLR4 was also increased in mini-BAL of S. In 52 
COPD peripheral blood, Foxp3 was reduced in comparison to C but no significant differences were 53 
observed for TLR4 and for IP-10. No significant differences were observed for IL-8 concentrations 54 
in the mini-BAL and in the blood of the recruited patients. The mini-BAL TLR4 expression 55 
correlated with the Clinical Infective Pulmonary Score. 56 
Conclusions. In exacerbated COPD patients with respiratory failure, lung and systemic reduced 57 
immune regulatory events (low Foxp3 expression) and lung increased innate immunity responses 58 
(high TLR4 expression) occur. These events may contribute to the increased inflammatory events 59 
leading to respiratory failure. 60 
61 
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INTRODUCTION 62 
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, is associated with 63 
pulmonary and extra-pulmonary clinical manifestations and includes different clinically relevant 64 
subtypes (1). One of the COPD subtypes is characterized by chronic bronchitis (CB). CB is a risk 65 
factor for accelerated lung function decline in COPD, increased hospitalization, and increased 66 
mortality (2). 67 
Cigarette smoke represents the most important risk factor for CB (3). Chronic oxidative stress of 68 
cigarette smoking induces mucus secretion and the increased mucus viscosity renders the airways 69 
susceptible to bacterial infections, a hallmark of CB (3).  70 
A key component of the innate immunity and of the innate defence mechanisms against infections 71 
is represented by the toll like receptor (TLR) family (4) . 72 
A recent hypothesis regarding COPD pathogenesis suggests as “step 1 of the disease” the activation 73 
of innate responses by injured tissue components (5). Products derived from epithelial cell injury 74 
can act as ligands for TLR4 and TLR2, thus amplifying inflammatory responses within the airways. 75 
Cigarette smoke is able to increase the expression of TLR4 and to orientate the activation of TLR4 76 
toward an increased release of IL-8 and a reduced release of interferon gamma-induced protein 10 77 
(IP-10) in bronchial epithelial cells (6). 78 
In the airways of COPD patients mechanically ventilated due to acute respiratory failure, there is an 79 
increased expression of TLR4 and an increased chemotactic activity toward neutrophils but a 80 
reduced concentration of IP-10 with a reduced chemotactic activity toward lymphocytes (7). The 81 
increased airway inflammation in the airways of COPD patients may also be sustained by the 82 
impairment of immune regulatory events and in particular may be linked to the reduced expression 83 
of the forkhead box P3 (Foxp3), a transcription factor crucially involved in T regulatory activities. 84 
COPD patients have, in small airways, decreased numbers of Foxp3 positive cells that negatively 85 
correlate with airflow obstruction (8) (9). Although COPD is associated with lung and systemic 86 
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inflammation, it is unknown whether the alteration in the innate and immune regulatory events 87 
observed in the airways of COPD patients are also present in the systemic compartment. 88 
The objectives of this study were to investigate the immune regulatory events and the inflammatory 89 
and the host defence responses in the airways and in the systemic compartment of COPD patients 90 
with CB.  Exacerbated COPD patients who experienced an acute respiratory failure requiring 91 
endotracheal intubation and mechanical ventilation were compared to patients requiring also 92 
intubation and mechanical ventilation but without COPD and without CB. In the recruited patients 93 
the expression of TLR4, the expression of Foxp3 and the release of specific chemokines (IP-10 and 94 
IL-8) were investigated. 95 
96 
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MATERIALS AND METHODS 97 
Patient population  98 
This study was conducted at the ICU of the Department of Anestesiology, Reanimation and 99 
Emergency of the University of Palermo, Italy. Local ethic committee permission and informed 100 
written consent from either the patient or closest  relatives were obtained. The patients were 101 
classified into the following groups: 1) subjects without smoking history, without history of 102 
previous CB or chronic pulmonary diseases including asthma and COPD and with acute respiratory 103 
failure upon surgery for abdominal or thoracic aneurysm, (Controls =C; n=10); 2) smoking subjects 104 
(>15 pack-year) with CB, without COPD and with acute respiratory failure upon surgery for 105 
abdominal or thoracic aneurysm (S; n=8); 3) smoking subjects (>15 pack-year) with CB with 106 
COPD (GOLD-1-2) and with acute respiratory failure upon treatment failure of an acute 107 
exacerbation (COPD; n=18).  The COPD patients fulfilled the diagnostic criteria of COPD (10) with 108 
a post-bronchodilator obstruction (FEV1 < 80% predicted, and FEV1/FVC ratio < 70%). Patients 109 
with x-ray or clinical evidence of sepsis or pneumonia at the time of mini-bronchoalveolar lavage 110 
(mini-BAL) collection were not included. CB were defined on the basis of symptoms and in 111 
particular productive cough lasting more than three months in more than two years. All recruited 112 
subjects required mechanical ventilation and underwent therapy with antibiotics and systemic 113 
corticosteroids (no significantly different doses among the patients included in the three groups). 114 
The antibiotics were adjusted to cover any identified pathogens on the basis of antibiograms. COPD 115 
patients, before COPD exacerbation, were undergoing therapy with bronchodilators but not with 116 
corticosteroids. Exacerbations were defined as previously reported (10) and were treated with 117 
antibiotics and systemic corticosteroids. At the ICU admission, data for Clinical Pulmonary 118 
Infective Score (CPIS), the simplified Acute Physiology Score (SAPS II) and sepsis-related organ 119 
failure assessment (SOFA) were collected from each recruited patient. Paired mini-BAL and blood 120 
samples were collected from all participants. Microbiology of mini-BAL was also assessed. 121 
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mini-BAL collection and processing 122 
 Distal lung fluid samples (mini-BAL) were obtained using BAL Cath system (by Kimberly Clark) 123 
within 1 h from the intubation. The protected catheter was blindly advanced through the 124 
endotracheal tube until it was wedged into a distal airway and aliquots of 10 ml of sterile 0.9% 125 
NaCl were instilled and gently suctioned (recovered volume about 70% of the instilled volume). 126 
Mini-BAL samples were filtered through a sterile gauze and then centrifuged at 1300 rpm for 10 127 
min to separate cells from supernatants. Total and differential (diff-quick staining) cell counts were 128 
assessed. The cell fraction was used for immunocytochemistry and western blot experiments. The 129 
supernatants were assessed for cytokine levels.  130 
Blood samples 131 
Blood samples (10 ml) were collected from C, S, COPD subjects and then processed for obtaining 132 
plasma and peripheral blood mononuclear cells (PBMC). PBMC were isolated from blood s by 133 
Ficoll-Hypaque (Pharmacia) gradient centrifugation. The cells were suspended in RPMI 1640 tissue 134 
culture medium (Invitrogen Life Technologies) supplemented with 1% heat-inactivated FCS 135 
(Invitrogen Life Technologies), 2 mM L-glutamine, 20 mM HEPES, 100 U/ml penicillin, 100 µg/ml 136 
streptomycin, 5 x 10–5 M 2-ME and 85 µg/ml gentamicin. Purity and viability were tested using 137 
trypan blue exclusion.  138 
Immunocytochemistry 139 
 The expression of TLR4 was evaluated using a rabbit polyclonal antibody (Santa Cruz 140 
Biotechnology).  Immunocytochemistry was performed using AP-LSAB2 (DAKO, Glostrup, 141 
Denmark) kit following the manufacturer’s instructions and new Fuchsin as chromogenic substrate 142 
(DAKO) (cytoplasmic red staining). Negative controls were performed using rabbit or mouse 143 
negative control immunoglobulins (DAKO).  Data are expressed as percentage of positive cells. 144 
Western blot analysis 145 
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The expression of Foxp3 was evaluated by western blot analysis as previously described  (11)  with 146 
minor modifications. 40 µg of total protein were loaded in the gel. All blots were probed using a 147 
goat polyclonal antibody anti-Foxp3 (1:100) (Santa Cruz Biotechnology, Santa Cruz,  CA). 148 
Membranes were then stripped and incubated with goat polyclonal anti–ß-actin (Sigma) as 149 
housekeeping protein to normalize differences in protein loading. Revelation was performed with an 150 
enhanced chemioluminescence system (GE Healthcare, Chalfont St. Giles, UK) followed by 151 
autoradiography. Negative controls were performed in the absence of primary antibody or including 152 
an isotype control antibody.  Data are expressed as densitometric arbitrary units by correction with 153 
the density of the bands obtained for beta-actin.  154 
Measurement of IL-8 and IP-10 155 
 The concentrations of IL-8 and IP-10 in plasma from C, S, CB-COPD subjects were determined by 156 
an enzyme-linked immunosorbent assays (ELISA) following the manufacturer’s instructions 157 
(Quantikine; R&D Systems, Minneapolis, MN). 158 
Statistics 159 
 Data are expressed as median (25-75 percentiles). Kruskal Wallis test was performed for 160 
comparisons among patient groups. A non-parametric Mann Whitney test was then applied as the 161 
initial Kruskal Wallis test was significant. The Wilcoxon test was used for comparisons between 162 
mini-BAL and autologous peripheral blood in each recruited patient. The Spearman test was used 163 
for correlations.  P< 0.05 was accepted as statistically significant. 164 
165 
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RESULTS 166 
Demographic characteristics of the subjects. 167 
The demographic characteristics of the three study groups are shown in Table 1. SAPS II and SOFA 168 
scores revealed no significant differences in the recruited patients. The CPIS score was significantly 169 
higher in COPD than in C (Table 1). No significant differences for CPIS score were shown in S in 170 
comparison to C and to COPD. The total and the differential cell counts of mini-BAL are shown in 171 
Table 2. Significantly higher numbers of total cells and of neutrophils were present in COPD 172 
patients. Microbiology of mini-BAL was shown in table 3. 173 
 174 
 Expression of TLR4 in cells from mini BAL and from peripheral blood cells.  175 
The percentage of TLR4 positive cells was significantly higher in mini-BAL cells from COPD and 176 
from S in comparison to mini-BAL from C. The percentage of TLR4 positive cells was significantly 177 
higher in mini-BAL cells from COPD in comparison to mini-BAL from S and to autologous 178 
peripheral blood (figure 1) (table 4). No significant differences in TLR4 expression were observed 179 
in peripheral blood cells among C, S and COPD (figure 1) (table 4).  180 
Concentrations of IL-8 and of IP-10 in mini BAL and in peripheral blood cells.  181 
The concentrations of IL-8 were significantly higher in mini-BAL of all the recruited patients (C, S 182 
and COPD patients) in comparison to autologous peripheral blood (figure 2). No significantly 183 
different concentrations of IL-8 were observed in mini-BAL and in peripheral blood among C, S 184 
and COPD (figure 2). The IP-10 concentrations were significantly reduced in mini-BAL from 185 
COPD in comparison to C and S and in comparison to autologous peripheral blood (figure 3). The 186 
IP-10 concentrations were significantly increased in peripheral blood from COPD in comparison to 187 
mini-BAL from C. No significantly different concentrations of IP-10 were observed in peripheral 188 
blood between S and C  (figure 3). 189 
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Expression of Foxp3 in mini BAL and in peripheral blood cells.  190 
In COPD and in S the expression of Foxp3 in mini-BAL and in peripheral blood was significantly 191 
lower than in C (figure 4 A-B) (table 4).. In COPD the expression of Foxp3 in mini-BAL and in 192 
peripheral blood was significantly lower than in S (figure 4 A-B) (table 4).. No significant 193 
differences were observed in the expression of Foxp3 in mini-BAL and in autologous peripheral 194 
blood in all the recruited patients. 195 
Correlations 196 
Finally, we tested whether the observed alterations in TLR4, Foxp3 and IP-10 in both lung and 197 
systemic compartments correlate with clinical scores of severity. CPIS correlates with mini-BAL 198 
TLR4 expression (figure 5) but not with the other markers (Foxp3 and IP-10) (data not shown). No 199 
significant correlations were observed between SOFA or SAPS II score with any of the tested 200 
markers (data not shown). 201 
202 
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DISCUSSION 203 
COPD is a heterogeneous disease and includes different clinically relevant subtypes. A divergent 204 
distribution of parenchymal (emphysema) and bronchial airway (chronic bronchitis) (CB) disease 205 
contributes to the phenotypic heterogeneity in COPD (12). COPD is associated not only with an 206 
abnormal inflammatory response in the lung but also with systemic inflammation, including 207 
systemic oxidative stress, activation of circulating inflammatory cells and increased circulating 208 
levels of inflammatory cytokines (12). The low–grade systemic inflammation present in COPD 209 
patients may be responsible for the systemic clinical manifestations of the disease including 210 
malnutrition, muscle wasting, osteoporosis, cardiovascular diseases, type II diabetes, anaemia and 211 
depression (13). 212 
This study explored whether lung and systemic inflammation occur concurrently and similarly in 213 
patients with acute respiratory failure with and without CB or COPD. We demonstrated for the first 214 
time that patients with both CB and COPD who underwent an acute exacerbation  have a different 215 
inflammatory profile (IP-10 levels) and a different alteration in the innate immune responses (TLR4 216 
expression) in the airways and in the systemic compartment. Differently, in these patients a similar 217 
alteration in the immune regulatory events (low Foxp3 expression) was observed in the airways and 218 
in the systemic compartment. The novel aspects underlined by the present study are related to the 219 
accurate selection of patients with a similar phenotype (CB) and a similar exposure to risk factor 220 
(cigarette smoke) in order to limit the variability of the obtained results and to better identify the 221 
role of the observed alterations in airway obstruction. Most of the studies report data from smoker 222 
or COPD patients with different phenotypes. 223 
CB is defined on the basis of chronic cough and sputum due to mucus hypersecretion and 224 
histologically, it is characterised by airway inflammation, hypertrophy of submucosal mucus 225 
secreting glands, and goblet cell hyperplasia (14). CB is a risk factor in COPD for accelerated lung 226 
function decline, increased hospitalization, and increased mortality (2). In this regard it has been 227 
demonstrated that the presence of CB may compromise the sterility of distal airway supporting the 228 
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hypothesis of natural progression from the simple mucus hypersecretion to purulent hypersecretion 229 
and obstructive bronchitis ( Hogg, Lancet 2004). Here, it is showed that the expression of TLR4 is 230 
increased in COPD patients with CB and acute exacerbation in the airways but not in the systemic 231 
compartment and this alteration is observed at lower extent also in smokers with CB but without 232 
COPD and without acute exacerbation. TLR4 expressed is associated in these patients with the 233 
presence of neutrophils which represent the predominant cell type in COPD patients. The data 234 
provided extend and integrate previous results from our group showing that in the airways of COPD 235 
patients with acute respiratory failure, there is an increased expression of TLR4 (7). Our data 236 
demonstrate that TLR4 expression is higher in mini-BAL cells in comparison to blood compartment 237 
suggesting an up-regulation of TLR4 at the transit from blood into the airway compartment. This 238 
phenomenon seems to be specific for TLR4 since it has been previously demonstrated that in COPD 239 
patients the expression of TLR2 is lower on sputum neutrophils in comparison to blood 240 
compartment indicating a down-regulation of TLR2 at the transit from blood into the airway 241 
compartment (16).  242 
TLR4 signaling, through MyD88 and IRAK1, plays a predominant role as a regulator of smoke-243 
induced protease production (17). Furthermore, CSE increase the expression of TLR4 but not of 244 
TLR2 and modify the functional activation of TLR4 generating an imbalance between cytokines 245 
with opposite functions such as IL-8 and IP-10 (6). IP-10 concentrations in mini-BAL of smoker 246 
COPD who are mechanically ventilated for acute exacerbation are reduced in comparison to another 247 
group of patients mechanically ventilated but not smokers and without COPD  (7). We confirm here 248 
the presence of reduced concentrations of IP-10 within the airways of mechanically ventilated and 249 
exacerbated COPD patients and demonstrate for the first time that within the systemic compartment 250 
in the same patients an increased concentration of IP-10 is observed in comparison to patients with 251 
acute respiratory failure but without CB and COPD. Nasal epithelial cells obtained from smokers 252 
create an overall cytokine microenvironment that after infection with influenza suppresses the 253 
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concentrations of IP-10 (18). When the bronchial epithelial cells were exposed to CSE, the release 254 
of IP-10 decreases while the release of IL-8 increases  (6). Although no significantly different 255 
concentrations of IL-8 were observed in mini-BAL and in peripheral blood between COPD, S and C 256 
within the airways the elevated concentrations of IL-8 are not balanced by elevated IP-10 257 
concentrations. The prevalence of IL-8 may in turn sustain the influx of neutrophils into the airways 258 
thus triggering innate immunity responses, while IP-10 attracts monocytes and lymphocytes (19) 259 
thus promoting activation of adaptative responses to efficiently and specifically limit microbial 260 
invasion and to restrain the harmful effects of prolonged neutrophil activation. The findings that 261 
mini-BAL from COPD had reduced IP-10 concentrations and reduced chemotactic activitites 262 
toward lymphocytes (7) might contribute to explain why the differential cell counts of mini-BAL 263 
from COPD failed to have lymphocytes and prompted us to explore whether lymphocyte regulatory 264 
activities were altered in these patients. CD4+ Foxp3+ regulatory T lymphocytes (Treg) are a 265 
subclass of CD4+ T cell receptor (TCR) αβ+ T cells that are essential to preserve immune 266 
homeostasis (20), (21). Stable expression of the transcription factor Foxp3 is a prerequisite for the 267 
maintenance of suppressive properties in CD4+ regulatory T cells. Foxp3 mRNA expression is not 268 
itself sufficient for stable Foxp3 protein expression (22). The epigenetic modifications, such as 269 
histone modification or DNA methylation, control regulatory T cells by controlling Foxp3 gene 270 
expression through altering the accessibility of the Foxp3 locus and by acetylating or deacetylating 271 
Foxp3 protein, thereby enabling the epigenetic regulation of Foxp3 target genes. Absence of the 272 
Foxp3 transcription factor at systemic level leads to the rapid development of fulminant multiorgan 273 
autoimmunity. A decreased Foxp3 expression in COPD patients and smokers parallels the 274 
aggravation of the disease (23). Patients with moderate or severe COPD upon fluticasone and 275 
salmeterol combination therapy show an increased proportion of Foxp3+Tregs in the total 276 
peripheral blood CD4+T cell population (24). Smokers with normal lung function and COPD 277 
patients have increased numbers of Foxp3-positive cells in large airways but they have decreased 278 
numbers of Foxp3-positive cells in small airways (25). In the patients with acute respiratory failure 279 
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recruited in the present study, the decreased expression of Foxp3 is present in smokers and in 280 
COPD in the distal airways and in the systemic compartment suggesting that the alterations in the 281 
immune regulatory activities are early events in the disease and may contribute to the systemic 282 
effects of the disease. It is conceivable that cigarette smoke may contribute to induce epigenetic 283 
modifications leading to the reduced expression of Foxp3 in smokers and in COPD smokers at both 284 
the airways and systemic compartment. No study has already specifically addressed this point yet. 285 
Finally, the relevance of the observed alterations in the severity of the recruited patients was 286 
assessed. Several commonly used scoring systems exist assessing the severity of the disease in 287 
critically ill patients by predicting mortality. In the present study the recruited patients were 288 
classified on the basis of their SOFA, SAPS II and CPIS score.  The mortality in elderly patients 289 
was higher than that of the younger patients and SAPS II (26) was an independent predictor of 290 
mortality in elderly patients with sepsis (27). The SOFA score, widely used in many cardiac 291 
surgical intensive units, is used for grading organ dysfunction or failing organ system (28) . 292 
Prognostic relevance of the SOFA score in combination with inflammatory parameters was also 293 
found in a recent study conducted by Zügel et al. (29). The CPIS score is calculated on the basis of 294 
points assigned for various signs and symptoms of pneumonia (eg, fever and extent of oxygenation 295 
impairment) and a CPIS >6 may serve as a surrogate tool to facilitate the diagnosis of ventilator-296 
associated pneumonia (30). In the present study, recruited patients have no significant different 297 
SOFA or SAPS II scores and these scores did not correlate with any of the tested markers. The only 298 
differences among the recruited patients were related to the CPIS score and CPIS score correlates 299 
with TLR4 mini-BAL expression. Future studies on a larger cohort of patients are needed to clarify 300 
whether the assessment of TLR4 expression in miniBAL may improve the predictive value of CPIS 301 
to early identify patients with ventilator-associated pneumonia. 302 
In conclusion, patients with both CB and COPD who underwent an acute exacerbation have a 303 
different alteration in the levels of IP-10 and in TLR4 expression in the airways and in the systemic 304 
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compartment while they have a similar alteration in Foxp3 expression in the airways and in the 305 
systemic compartment. The inflammatory profile of the COPD patients in the present study may be 306 
the result of the failure to properly clear the inflammatory cells after the exacerbation of the disease. 307 
308 
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LEGENDS TO THE FIGURES 413 
Figure1. Increased expression of TLR4 in mini-BAL but not in the peripheral blood of S and 414 
of COPD. Mini-BAL cells and paired blood samples were recovered from C (n=10), from S (n=8) 415 
and from COPD (n=18)  patients. The expression of TLR4 was assessed by immunocytochemistry 416 
using an anti-TLR4 polyclonal antibody; * p<0.05 vs C; ** p<0.05 vs S;  # p<0.05 vs autologous 417 
peripheral blood. Data are expressed as median (25-75 percentiles). 418 
Figure 2. Absence of differences in the concentrations of IL-8 in mini-BAL and in  the 419 
peripheral blood of S and of COPD. Mini-BAL supernatants and paired blood samples were 420 
recovered from C (n=10), from S (n=8) and from COPD (n=18) patients.  IL-8 concentrations were 421 
measured by ELISA as described in "materials and methods" and are expressed as pg/ml. Data are 422 
expressed as median (25-75 percentiles). 423 
Figure 3. Reduced concentrations of IP-10 in mini-BAL but not in  the peripheral blood of 424 
COPD. Mini-BAL supernatants and paired blood samples were recovered from C (n=10), from S 425 
(n=8) and from COPD (n=18) patients.  IP-10 concentrations were measured by ELISA as 426 
described in "materials and methods" and are expressed as pg/ml.  * p<0.05 vs C; ** p<0.05 vs S;  # 427 
p<0.05 vs autologous peripheral blood. Data are expressed as median (25-75 percentiles). 428 
Figure 4. Reduced expression of Foxp3 in mini-BAL and in  the peripheral blood of S and of 429 
COPD. Mini-BAL cells and paired blood samples were recovered from C (n=10), from S (n=8) and 430 
from COPD (n=18) patients. Total proteins were extracted and analysed for Foxp3 expression by 431 
western blot analysis. Membranes were then stripped and incubated with goat polyclonal anti–ß-432 
actin.. A. Densitometric analysis of Foxp3 expression. Signals corresponding to Foxp3 on the 433 
various western blots were semiquantified by densitometric scanning, normalized and expressed 434 
after correction with the density of the band obtained for beta-actin (mean±SD). * p < 0.05.  B. 435 
Representative western blot analysis for Foxp3 expression from  C, S and COPD subjects. Data are 436 
expressed as median (25-75 percentiles). 437 
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Figure 5. Correlations between the expression of TLR4 in miniBAL and CPIS score. The 438 
expression of TLR4 in mini-BAL of C (n=10),  S (n=8) and COPD (n=18) was correlated with 439 
CPIS score by Spearman Correlation test. 440 
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 1 
Table 1: Demographic and clinical characteristics of the subjects: 2 
 3 
 4 
Characteristic C S COPD P value 
No. of subjects 10 8 18  
Age (yr) 73 (72-78) 79.5 (76-82) 76 (71-81) n.s. 
Male/Female 7/3 5/3 11/7 n.s. 
Cigarette smoke 
Packs/years 
- 45±20 50±21 n.s. 
FEV1( % of  predicted 
normal) 
85±2.5 87±3.9 67±5* *p<0.05 
COPD vs C and S  
FEV1/FVC ( % of  
predicted normal) 
77±3 76±2 65±2* *p<0.05 
COPD vs C and S  
CPIS 2.3±1.1 3.3±1.4 3.7±0.9* *P<0.05 
COPD vs C  
SOFA 9.1±1.2 8.7±1.3 8.9±1 n.s. 
SAPS II 53.6±7.8 59.5±11 56±7 n.s. 
 5 
 6 
Data are expressed as percentiles (age) or as mean ± SD.  7 
 8 
 9 
 10 
 11 
 12 
 13 
  14 
 15 
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Table 2: Total and differential cell counts of mini-BAL 1 
  2 
 3 
 C =10 S=8 COPD=18 P value 
Mini-BAL cells 
Total number 
(X1000)/ml 
536±269 919±167* 3,2±2,400* * p<0.05 
COPD and S vs C  
% Neutrophils 46±30 48±17 83±13*       *p<0.05 
COPD vs C and S  
 
% Macrophages 51±29 52±16 17±13* *p<0.05 
COPD vs C and S  
% Lymphocytes 2.7±1.3 0* 0* *p<0.05 
COPD and S vs C 
 4 
Results are expressed as mean ± SD. 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
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Table 2: Microbiology of miniBAL 
 
 C with  
MiniBAL cultures 
 Positive (n=4) 
C with  
Mini BAL 
cultures 
 Negative (n=6) 
CFU 
Patient#1  X  
Patient#2  X  
Patient#3 Candida  ≥10
3
/ml 
Patient#4 Candida  ≥10
3
/ml 
Patient#5  X  
Patient#6  X  
Patient#7 Candida  ≥10
3
/ml 
Patient#8  X  
Patient#9  X  
Patient#10 Candida  ≥10
3
/ml 
 S with  
MiniBAL cultures 
 Positive (n=3) 
S with  
Mini BAL 
cultures 
 Negative (n=5) 
CFU 
Patient#1  X  
Patient#2  X  
Patient#3 Candida  ≥10
3
/ml 
Patient#4 Candida  ≥10
3
/ml 
Patient#5  X  
Patient#6  X  
Patient#7  X  
Patient#8 Acinetobacter 
Baumannii 
 ≥10
3
/ml 
 COPD with MiniBAL cultures 
positive (n=7) 
COPD with Mini 
BAL cultures 
negative (n=11) 
CFU 
Patient#1 Candida  ≥10
3
/ml 
Patient#2  X  
Patient#3  X  
Patient#4 Acinetobacter Baumannii  ≥10
3
/ml 
Patient#5  X  
Patient#6 Candida  ≥10
3
/ml. 
Patient#7  X  
Patient#8 Pseudomonas Aeruginosa  ≥10
3
/ml 
Patient#9  X  
Patient#10 Acinetobacter Baumannii  ≥10
3
/ml 
Patient#11  X  
Patient#12  X  
Patient#13 Candida  ≥10
3
/ml 
Patient#14  X  
Patient#15  X  
Patient#16 Pseudomonas Aeruginosa  ≥10
3
/ml 
Patient#17  X  
Patient#18  X  
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Table 2: Total and differential cell counts of mini-BAL 1 
  2 
 3 
 C =10 S=8 COPD=18 P value 
TLR4 expression 
in Mini-BAL cells 
(% of positive cells) 
 
21.9±6.4 39.8±3.8 64.88±4.8 *p<0.05 
COPD and S vs C 
TLR4 expression 
in peripheral blood 
cells 
(% of positive cells) 
25.4±6.5 17.5±1.76 26.8±6.37 n.s. 
 
Foxp3 expression 
in Mini-BAL cells 
(arbitrary units) 
 
2.5±0.24 1.83±0.12* 1.39±0.41* *p<0.05 
COPD and S vs C  
Foxp3 expression 
in peripheral blood 
cells 
(arbitrary units) 
3.79±0.3 2.36±0.36 1.75±0.53 *p<0.05 
COPD and S vs C 
 4 
Results are expressed as mean ± SE.  5 
* Mann Whitney test 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
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